Literature DB >> 10410676

Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.

C C Huang1, P W Faber, F Persichetti, V Mittal, J P Vonsattel, M E MacDonald, J F Gusella.   

Abstract

Huntington's disease (HD) is caused by an expanded CAG trinucleotide repeat encoding a tract of consecutive glutamines near the amino terminus of huntingtin, a large protein of unknown function. It has been proposed that the expanded polyglutamine stretch confers a new property on huntingtin and thereby causes cell and region-specific neurodegeneration. Genotype-phenotype correlations predict that this novel property appears above a threshold length (approximately 38 glutamines), becomes progressively more evident with increasing polyglutamine length, is completely dominant over normal huntingtin and is not appreciably worsened by a double genetic dose in HD homozygotes. Recently, an amino terminal fragment of mutant huntingtin has been found to form self-initiated fibrillar aggregates in vitro. We have tested the capacity for aggregation to assess whether this property matches the criteria expected for a fundamental role in HD pathogenesis. We find that that in vitro aggregation displays a threshold and progressivity for polyglutamine length remarkably similar to the HD disease process. Moreover, the mutant huntingtin amino terminus is capable of recruiting into aggregates normal glutamine tract proteins, such as the amino terminal segments of both normal huntingtin and of TATA-binding protein (TBP). Our examination of in vivo aggregates from HD post-mortem brains indicates that they contain an amino terminal segment of huntingtin of between 179 and 595 residues. They also contain non-huntingtin protein, as evidenced by immunostaining for TBP. Interestingly, like the in vitro aggregates, aggregates from HD brain display Congo red staining with green birefringence characteristic of amyloid. Our data support the view that the expanded polyglutamine segment confers on huntingtin a new property that plays a determining role in HD pathogenesis and could be a target for treatment. Moreover, the new property might have its toxic consequences by interaction with one or more normal polyglutamine-containing proteins essential for the survival of target neurons.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10410676     DOI: 10.1023/b:scam.0000007124.19463.e5

Source DB:  PubMed          Journal:  Somat Cell Mol Genet        ISSN: 0740-7750


  84 in total

1.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

Authors:  J S Steffan; A Kazantsev; O Spasic-Boskovic; M Greenwald; Y Z Zhu; H Gohler; E E Wanker; G P Bates; D E Housman; L M Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Specificity in intracellular protein aggregation and inclusion body formation.

Authors:  R S Rajan; M E Illing; N F Bence; R R Kopito
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

3.  Polyglutamine fibrillogenesis: the pathway unfolds.

Authors:  Christopher A Ross; Michelle A Poirier; Erich E Wanker; Mario Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-30       Impact factor: 11.205

Review 4.  Huntingtin in health and disease.

Authors:  Anne B Young
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

5.  A structural model of polyglutamine determined from a host-guest method combining experiments and landscape theory.

Authors:  John M Finke; Margaret S Cheung; José N Onuchic
Journal:  Biophys J       Date:  2004-09       Impact factor: 4.033

6.  Huntington's disease and mitochondrial alterations: emphasis on experimental models.

Authors:  Verónica Pérez-De la Cruz; Paul Carrillo-Mora; Abel Santamaría
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

7.  Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis.

Authors:  Jonathan A Sayer; Maria Manczak; Lakshmi Akileswaran; P Hemachandra Reddy; Vincent M Coghlan
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

8.  Allele-specific conditional destabilization of glutamine repeat mRNAs.

Authors:  Andrew B Crouse; Peter J Detloff
Journal:  Gene Expr       Date:  2005

9.  Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation.

Authors:  Atsushi Iwata; John C Christianson; Mirella Bucci; Lisa M Ellerby; Nobuyuki Nukina; Lysia S Forno; Ron R Kopito
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

10.  Interactions between homopolymeric amino acids (HPAAs).

Authors:  Yoko Oma; Yoshihiro Kino; Kazuya Toriumi; Noboru Sasagawa; Shoichi Ishiura
Journal:  Protein Sci       Date:  2007-08-31       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.